Navigation Links
Argonne, University of Chicago Scientists Develop Targeted Cancer Treatment Using Nanomaterials
Date:8/19/2009

Nano-bio material kills cancer cells, leaves healthy cells in unharmed

Argonne, Ill. (Vocus) August 19, 2009 -- Scientists from the U.S. Department of Energy's (DOE) Argonne National Laboratory and the University of Chicago's Brain Tumor Center have developed a way to target brain cancer cells using inorganic titanium dioxide nanoparticles bonded to soft biological material.

Thousands of people die from malignant brain tumors every year, and the tumors are resistant to conventional therapies. This nano-bio technology may eventually provide an alternative form of therapy that targets only cancer cells and does not affect normal living tissue.

"It is a real example of how nano and biological interfacing can be used for biomedical application," said scientist Elena Rozhkova with Argonne's Center for Nanoscale Materials. "We chose brain cancer because of its difficulty in treatment and its unique receptors."

This new therapy relies on a two-pronged approach. Titanium dioxide is a versatile photoreactive nanomaterial that can be bonded with biomolecules. When linked to an antibody nanoparticles recognize and bind specifically to cancer cells. Focused visible light is shined onto the affected region, and the localized titanium dioxide reacts to the light by creating free oxygen radicals that interact with the mitochondria in the cancer cells. Mitochondria act as cellular energy plants, and when free radicals interfere with their biochemical pathways, mitochondria receive a signal to start cell death.

"The significance of this work lies in our ability to effectively target nanoparticles to specific cell surface receptors expressed on brain cancer cells," said Dr. Maciej S. Lesniak, Director of Neurosurgical Oncology at University of Chicago Brain Tumor Center. "In so doing, we have overcome a major limitation involving the application of nanoparticles in medicine, namely the potential of these agents to distribute throughout the body. We are now in a position to develop this exciting technology in preclinical models of brain tumors, with the hope of one day employing this new technology in patients."

X-ray fluorescence microscopy done at Argonne's Advanced Photon Source also showed that the tumors' invadopodia, actin-rich micron scale protrusions that allow the cancer to invade surrounding healthy cells, can be also attacked by the titanium dioxide.

So far, tests have been done only on cells in a laboratory setting, but animal testing is planned for the next phase. Results show an almost 100 percent cancer cell toxicity rate after six hours of illumination, and 80 percent after 48 hours.

Also, since the antibody only targets the cancer cells, surrounding healthy cells are not affected, unlike other cancer treatments such as chemotherapy and radiotherapy.

Rozhkova said that a proof of concept is demonstrated, and other cancers can be treated as well using different targeting molecules, but research is in the early stages.

This work is published in a Nano Letters and is available online at http://pubs.acs.org/doi/full/10.1021/nl901610f.

Funding for this research was through the Department of Energy's Office of Basic Energy Sciences, National Cancer Institute, National Institute of Neurological Disorders and Stroke, Alliance for Cancer Gene Therapy, American Cancer Society and Brain Research Foundation.

The U.S. Department of Energy's Argonne National Laboratory seeks solutions to pressing national problems in science and technology. The nation's first national laboratory, Argonne conducts leading-edge basic and applied scientific research in virtually every scientific discipline. Argonne researchers work closely with researchers from hundreds of companies, universities, and federal, state and municipal agencies to help them solve their specific problems, advance America's scientific leadership and prepare the nation for a better future. With employees from more than 60 nations, Argonne is managed by UChicago Argonne, LLC for the U.S. Department of Energy's Office of Science.

The Center for Nanoscale Materials at Argonne is one of the five DOE Nanoscale Science Research Centers (NSRCs), premier national user facilities for interdisciplinary research at the nanoscale. Together the NSRCs comprise a suite of complementary facilities that provide researchers with state-of-the-art capabilities to fabricate, process, characterize and model nanoscale materials, and constitute the largest infrastructure investment of the National Nanotechnology Initiative. The NSRCs are located at DOE's Argonne, Brookhaven, Lawrence Berkeley, Oak Ridge and Sandia and Los Alamos National Laboratories. For more information about the DOE NSRCs, please visit http://nano.energy.gov.

Contact:
Brock Cooper
(630) 252-5565

# # #

Read the full story at http://www.prweb.com/releases/cancer_medicine/cancer_treatment/prweb2771014.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Argonne, University of Chicago scientists develop targeted cancer treatment using nanomaterials
2. University of Iowa professor identifies new eating disorder
3. University of Wisconsin Hospitals and Clinics Complete System-Wide Conversion to Masimo SET Pulse Oximetry Technology
4. University of Texas Study Details Lengthy Payment Delays for Medicare Part D Prescription Drug Claims, Confirming Need for Legislative Fix
5. Tulane University to receive $14M for international HIV/AIDS program
6. University of Nevada School of Medicine Professor Confirms Accuracy Through Validation Study Using the CSI Health Station Model 6K
7. Boston University School of Medicine researcher recipient of Memory Ride Grant
8. Loma Linda University Medical Center Selects Beryl to Manage Call Center Interactions for Womens Services Programs and Departments
9. Medina General Hospital and University Hospitals Agree to Pursue Affiliation
10. J.D. Power and Associates Reports: Hackensack University Medical Center Recognized as First Hospital to Achieve Distinction for Providing an Outstanding Inpatient Experience in All Four Service Areas
11. The First Incisionless Transoral Fundoplication for Treatment of Gastroesophageal Reflux is Performed in the U.S. at Ohio State University and Oregon Health & Science University Medical Centers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Argonne, University of Chicago Scientists Develop Targeted Cancer Treatment Using Nanomaterials 
(Date:2/11/2016)... AR (PRWEB) , ... February 11, 2016 , ... Dickinson ... their community by announcing a new fundraiser in support of a local boy named ... hopes the campaign will bring awareness to, and rally support for, all local families ...
(Date:2/11/2016)... ... February 11, 2016 , ... From March 4 through 6, ... Annual Meeting at the Walter E. Washington Convention Center in Washington, D.C. , ... condition of hyperhidrosis (excessive sweating) and its treatment options. Specifically, the company will ...
(Date:2/11/2016)... , ... February 11, 2016 , ... The book, “Computers ... IT services, what questions to ask your IT consultant before signing a contract and ... your computer network. , “With companies relying heavily on e-mail and technology, it’s more ...
(Date:2/10/2016)... ... February 10, 2016 , ... The 9th annual meeting ... Congress (WMIC), will be held in New York City, NY on September 7 ... The congress will highlight and emphasize how imaging reveals a greater understanding of ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... company offering education, research and medical media, has launched Contagion® , ... infectious diseases. , As the all-inclusive resource for infectious disease information, Contagion ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... F ast ... at the point of ... technical and medical information products and services, has launched a ClinicalKey ... information via a mobile device. Elsevier designed the mobile app to allow ... app is available in Android and iOS formats ...
(Date:2/11/2016)... Fla. , Feb. 11, 2016 ... ) company providing high-quality specialty pharmacy care for ... announced today it has achieved full Specialty Pharmacy ... accrediting organization dedicated to promoting health care quality ... --> --> The URAC accreditation ...
(Date:2/11/2016)... "team investment" by Bruce Montgomery , one of this area,s most prominent biotech executives, and ... Kawas , PhD. Photo - http://photos.prnewswire.com/prnh/20160211/332242 ... ... ... Kawas said the round was intended to be an $8 million raise ...
Breaking Medicine Technology: